Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells $16,734.90 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 3,678 shares of the business’s stock in a transaction on Monday, April 7th. The shares were sold at an average price of $4.55, for a total transaction of $16,734.90. Following the completion of the sale, the chief financial officer now directly owns 89,868 shares in the company, valued at $408,899.40. This represents a 3.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Molly Henderson also recently made the following trade(s):

• On Tuesday, January 21st, Molly Henderson sold 6,583 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $6.59, for a total value of $43,381.97.

Phathom Pharmaceuticals Stock Performance

Shares of PHAT stock opened at $4.11 on Friday. Phathom Pharmaceuticals, Inc. has a 52-week low of $3.81 and a 52-week high of $19.71. The stock has a market cap of $286.21 million, a price-to-earnings ratio of -0.72 and a beta of 0.35. The firm’s 50-day moving average is $5.47 and its 200-day moving average is $9.16.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald raised Phathom Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th. The Goldman Sachs Group cut their price objective on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a “neutral” rating on the stock in a research report on Monday, March 10th. HC Wainwright reiterated a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. Guggenheim reissued a “buy” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, April 2nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $22.17.

Institutional Trading of Phathom Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Wasatch Advisors LP increased its holdings in shares of Phathom Pharmaceuticals by 531.3% during the 4th quarter. Wasatch Advisors LP now owns 1,558,928 shares of the company’s stock worth $12,658,000 after acquiring an additional 1,311,986 shares during the last quarter. FMR LLC increased its holdings in shares of Phathom Pharmaceuticals by 49,000.7% in the third quarter. FMR LLC now owns 1,304,114 shares of the company’s stock valued at $23,578,000 after purchasing an additional 1,301,458 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Phathom Pharmaceuticals by 20.4% in the fourth quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock valued at $57,348,000 after purchasing an additional 1,196,118 shares during the last quarter. Tang Capital Management LLC bought a new position in shares of Phathom Pharmaceuticals in the fourth quarter valued at about $4,060,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Phathom Pharmaceuticals during the 4th quarter worth about $3,701,000. 99.01% of the stock is owned by institutional investors and hedge funds.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.